Skip to content

A placebo-controlled, two-period crossover clinical trial concerning the effect on cerebral function by taking test beverage.

A placebo-controlled, single blind, two-period crossover, comparative superiority clinical trial concerning the effect on cerebral function by taking test beverage. - A placebo-controlled, single blind, two-period crossover, comparative superiority clinical trial concerning the effect on cerebral function by taking test beverage.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052419
Enrollment
40
Registered
2023-10-11
Start date
2023-10-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Take 200 mL test food sitting at rest taking 5 minutes Take 200 mL placebo food sitting at rest taking 5 minutes

Sponsors

IMEQRD Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Healthy male adults aged between 20 and 35 2. BMI less than 25.0 kg/m^2 3. No smoker (No smoking past one year) 4. Received a sufficient explanation for the study objective, and voluntarily joined the study with the agreement to informed consent

Exclusion criteria

Exclusion criteria: 1.Receiving continuous pharmaceutical treatment with drugs including commercial pharmaceuticals and Chinese medicines excluding use as needed 2.Receiving any dietary or exercise treatment under medical doctors 3.Current or a history of mental disease, sleep disorder, hypertension, diabetes, dyslipidemia, or serious illness 4.Current or a history of serious disorders of the liver, kidneys, heart, lungs, blood 5.A gastrointestinal comorbidity or serious medical history 6.Using implanted medical devices containing pacemakers or blood vessel clips 7.A habit of taking drugs for treating diseases in past one month, excluding use of drugs for headaches, colds 8.Have been taking foods with functional health claims that affect autonomic nervous system, metabolism and sleep, excluding who can quit intake during the study 9.A constitutional difficulty in drinking alcohol 10.At risk of developing hay fever or seasonal allergy symptoms or have allergic rhinitis during the study period. 11.Have or at risk of developing drug or food allergy symptoms 12.Have difficulty wearing a heart rate monitor, such as an allergy to tape 13.Alcohol drinkers, over 40 g/day of alcohol 14.Extremely irregular eating habits 15.Shift workers 16.Under significant stress of any life event within 3 months before IC, or will have such a life event during the study period 17.Have participated another clinical study within 1 month before IC, or will participate in it during the study period or within 1 month after the end of the study 18.Cannot quit drinking from the day before the test date 19.Have claustrophobia 20.Current or a history of mental disorder containing depression 21.A history of head surgery 22.Using electrical nerve stimulation devices 23.Have any tattoos 24.Have metal fragments in their body 25.Undergoing implant treatment 26.Wearing orthodontic bridges 27.Severe visual impairment, taste impairment, or olfactory impairment 28.Unsuitable for the study judged by the investigator

Design outcomes

Primary

MeasureTime frame
fMRI

Secondary

MeasureTime frame
Questionnaire concerning psychological evaluation pulse rate

Countries

Japan

Contacts

Public ContactHirokuni Kayama

IMEQRD Co., Ltd Planning and Sales Department

clinical-trial@imeqrd.co.jp03-6704-5968

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026